›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Follow It®
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Canexia HealthType:
Laboratory Developed Test
Related tests:
Follow It is an amplicon-based focused liquid biopsy panel that analyzes cell-free circulating tumor DNA (ctDNA) in plasma isolated from peripheral blood. The assay is designed to detect SNVs and CNVs commonly associated with multiple solid tumor types, as well as MSI-status. Follow It detects common, clinically relevant genomic alterations in solid tumor samples, including single-base substitutions (SNVs), small deletions, and insertions (up to 24bp). It evaluates the mutation status of tumor DNA at 337 hotspots and 26 exons in 38 known cancer-associated genes simultaneously.
Cancer:
Basal Cell Carcinoma, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastrointestinal Stromal Tumor, Melanoma, Non Small Cell Lung Cancer, Solid Tumor
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), BRAF (B-raf proto-oncogene), CTNNB1 (Catenin (cadherin-associated protein), beta 1), DDR2 (Discoidin domain receptor 2)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), BRAF (B-raf proto-oncogene), CTNNB1 (Catenin (cadherin-associated protein), beta 1), DDR2 (Discoidin domain receptor 2), DICER1 (Dicer 1 Ribonuclease III), EGFR (Epidermal growth factor receptor), ER (Estrogen receptor), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FOXL2 (Forkhead Box L2), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MET (MET proto-oncogene, receptor tyrosine kinase), MSI (Microsatellite instability), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), POLE (DNA Polymerase Epsilon), PTCH1 (Patched 1), PTEN (Phosphatase and tensin homolog), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), STK11 (Serine/threonine kinase 11), TP53 (Tumor protein P53)
Method:
Liquid biopsy
